Rights and permissions
About this article
Cite this article
US FDA addresses postmarketing drug surveillance concerns. React. Wkly. 1030, 3 (2004). https://doi.org/10.2165/00128415-200410300-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-200410300-00006